The MYG1 knockout T-47D polyclonal cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the mitochondrial protein MYG1 (also known as C12orf10) in the human breast cancer cell line T-47D. This genetically heterogeneous knockout pool is generated through CRISPR/Cas9-mediated target-gene disruption, providing a robust loss-of-function model for examining the role of MYG1 in mitochondrial metabolism and cellular energetics. Unlike clonal isolates, the polyclonal format captures a broader representation of genetic perturbations, minimizing clonal artifacts and facilitating population-level analyses of mitochondrial function.
The T-47D cell line is a well-established in vitro model of human breast carcinoma, originally derived from the pleural effusion of a patient with ductal carcinoma. These cells exhibit an epithelial morphology and retain key features of luminal A breast cancer, including expression of estrogen and progesterone receptors, rendering them particularly valuable for studying hormone-dependent tumor biology and metabolic adaptations in breast cancer. Their stable growth characteristics and responsiveness to hormonal stimuli make T-47D cells a suitable host for investigating the interplay between mitochondrial function and cancer cell physiology.
MYG1 encodes an evolutionarily conserved mitochondrial protein implicated in the regulation of mitochondrial metabolism and energy homeostasis. As part of the broader mitochondrial gene expression machinery, MYG1 interacts with mitochondrial ribosomal proteins and electron transport chain complexes, and its expression is under the transcriptional control of key biogenesis regulators such as NRF1, TFAM, and PGC-1??. Consequently, MYG1 is positioned to influence downstream outputs including mitochondrial oxidative phosphorylation, ATP production, and reactive oxygen species (ROS) generation. Disruption of MYG1 by CRISPR/Cas9 leads to impaired oxidative phosphorylation, elevated ROS levels, and altered cellular energy metabolism, thereby perturbing the balance between mitochondrial bioenergetics and cell survival pathways.
In the context of T-47D breast carcinoma cells, MYG1 knockout provides a physiologically relevant platform to dissect mitochondrial contributions to breast cancer cell behavior. Breast cancer cells, particularly those of the luminal subtype, often reprogram their metabolism to sustain proliferation and evade apoptosis, and mitochondrial dysfunction can unmask metabolic vulnerabilities or modulate sensitivity to therapeutic agents. By disabling MYG1, this model enables researchers to explore how disrupted mitochondrial metabolism affects cell proliferation, apoptosis, and drug resistance, offering insights into potential metabolic liabilities in hormone-responsive breast cancer.
This knockout model is ideally suited for a variety of experimental approaches, including mitochondrial stress testing via the Seahorse Analyzer, quantification of ROS production, cell proliferation and apoptosis assays, as well as molecular profiling by western blotting and RT-qPCR. It serves as a valuable tool for investigating mitochondrial metabolism in breast cancer, studying mechanisms of drug resistance, and exploring metabolic vulnerabilities that could be exploited therapeutically. For additional information or technical support, please contact Ascent Research.
